Paradigm Biopharmaceuticals' Phase 3 Knee Osteoarthritis Trial to Continue Unchanged Following Safety Board Recommendation
MT Newswires Live
Aug 13
Paradigm Biopharmaceuticals (ASX:PAR) said an independent Data Safety Monitoring Board recommended that the company's phase 3 clinical trial of a knee osteoarthritis treatment continue without modification, according to a Thursday filing with the Australian bourse.
The trial is evaluating injectable pentosan polysulfate sodium in participants with knee osteoarthritis, with the change in pain intensity at day 112 set as the primary endpoint.
The safety board issued the recommendation after completing a review of about 80% of the participants who have completed dosing, the company said.
The trial's interim analysis remains on track for September.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.